TRUE Test

Quick links to important sections

TRUE Test

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of TRUE Test

Property Description
Active ingredient 35 standardized allergens (haptens)
Form Ready-to-use Epicutaenous patch
Pharmacological Class Diagnostic Agent / Allergen Patch Test System
Common Use Identifying causes of Allergic Contact Dermatitis (ACD)
Distinctive Feature Patches are pre-applied to a single tape panel

Defining the TRUE Test: A Diagnostic System

The TRUE Test (Thin-Layer Rapid Use Epicutaneous Test) is a standardized, ready-to-use diagnostic system utilized by dermatologists to identify the specific substances causing Allergic Contact Dermatitis (ACD). It is formally categorized as an Allergen Patch Test System, placing it within the high-level Diagnostic Agent pharmacological class. This system is clinically recognized for its reliability in identifying common contact allergies. The primary purpose of this test is not treatment but to provide necessary diagnostic information.


What Is Included in the TRUE Test?

The TRUE Test is a combination patch test that features 35 standardized allergens and one negative control patch, distinguishing it as a comprehensive screening tool. These allergens, or haptens, which serve as the test's active ingredients, include substances known to be common causes of ACD, such as Nickel sulfate, Fragrance mix, and Potassium dichromate. Unlike older, manually applied patch test systems, the TRUE Test is a ready-to-use, single-panel system where the patches are pre-coated in a dry, hydrophilic gel film on a non-woven backing. This feature ensures a highly reliable and uniform dose.


Why is the TRUE Test Important for Diagnosis?

The TRUE Test is essential for diagnosis because it provides clear, actionable information by directly identifying the substance responsible for a patient's contact allergy. It works by assessing the skin's delayed immune response when the patches are applied to the back (the route of administration is epicutaneous). Avoiding contact with known allergens is the primary treatment method for ACD. Once the trigger is identified by the test, the patient can begin effective avoidance strategies. By determining which specific chemicals or metals the patient must avoid, the test empowers both the patient and the healthcare provider to eliminate the source of the allergic reaction, thus managing their chronic skin inflammation.

Regulatory References

  1. National Institutes of Health (NIH)
  2. The NIH states

What side effects are possible with TRUE Test?

Possible Side Effects and Safety Information

The T.R.U.E. Test is an epicutaneous patch test used as an aid in the diagnosis of allergic contact dermatitis. As the test intentionally exposes the skin to common allergens, the safety profile is primarily characterized by localized skin reactions and, rarely, severe systemic events.

Serious and Clinically Significant Adverse Reactions

The most significant safety risk is the potential for acute allergic reactions, including anaphylaxis, which may be life-threatening and require immediate medical attention.

Furthermore, the regulatory documentation includes warnings for potential skin-related issues that can complicate test interpretation or persist, such as:

  • Sensitization: The development of a new allergy to one or more of the test allergens with initial or repeat testing.
  • Persistent Reactions: Test reactions that remain visible for weeks or months after the panels are removed.
  • Excited Skin Syndrome (also known as 'Angry Back').
  • Extreme Positive Reactions and Irritant Contact Dermatitis at the test site.

Common Adverse Reactions

The most frequently reported adverse reactions, occurring in more than 1% of the adult study population, are predominantly confined to the application site:

System-Organ Class Common Adverse Reactions (>1% in adults)
Application Site Reactions Burning, Tape Irritation, Persistent Reactions, Erythema, Hyper/Hypopigmentation

In children and adolescents (ages 6 through 17), localized adverse reactions occurred at higher frequencies, including itching and tape irritation (up to 61.2% and 50.0%, respectively), along with ectopic flare of pre-existing dermatitis.

Safety Limitations and Precautions

Testing is contraindicated in individuals with a known history of allergic reaction to the T.R.U.E. Test or its components. The test must only be applied to healthy skin free of conditions like scars or active dermatitis that could interfere with results. Recent excessive sun exposure or UV treatment to the test site should be avoided, as this may increase the risk of false-negative results. The use of systemic or topical immunosuppressant therapies may suppress or diminish the skin reaction to the test allergens.

Overdose and Emergency Response

Overdose and When to Seek Help

The TRUE Test system is a diagnostic agent for epicutaneous use, meaning that traditional systemic pharmacological overdose is not the primary regulatory concern. The official overdose profile focuses strictly on the consequences of accidental ingestion of the patch components or excessive, non-standard application (misuse).

Manifestations of misuse include an exaggerated local skin reaction at the application site, presenting as intense erythema, pronounced papules, or excessive vesicles. Severe outcomes documented in regulatory texts include severe spreading contact dermatitis and, rarely, localized skin ulceration or necrosis. Accidental oral ingestion may result in mucosal irritation and carries a documented risk of systemic hypersensitivity, particularly in pediatric patients.

Emergency Action Mandates

Official regulatory guidance requires the user to seek immediate medical attention for all cases of suspected overdose or accidental exposure. Contact emergency services immediately is mandated if any signs of a systemic reaction occur, such as difficulty breathing. Treatment is uniformly described as symptomatic and supportive, as no specific antidote is known for the complex mixture of haptens. Hospital observation may be required for severe cutaneous reactions or accidental ingestion.

Therapeutic Uses of TRUE Test

What TRUE Test Treats: Main Uses and Benefits

The TRUE Test system is commonly used as a foundational diagnostic aid in dermatology and allergology, supporting the management of specific skin diseases by helping to identify their underlying cause. The system is considered relevant for use as an aid in the diagnosis of Allergic Contact Dermatitis (ACD) in persons 6 years of age and older whose history suggests sensitivity to common allergens.

The test is relevant for easing conditions presenting with recurrent or chronic eczematous manifestations like redness, scaling, flaking, and discomfort. The diagnostic clarity offered by the TRUE Test assists with maintaining functional stability by addressing the source of significant, distressing symptoms, including persistent pruritus (itching) and recurrent inflammatory lesions. The core therapeutic benefit is providing the actionable information that supports the implementation of a precise avoidance strategy—a cornerstone of ACD management.

The test is commonly used in clinical scenarios involving suspected occupational exposures or reactions to everyday products like jewelry and cosmetics.

“By identifying the specific allergen, the patient receives support for easing distress related to inflammation.”

Quick Fact: Relief for Chronic Skin Discomfort
The diagnostic result supports general well-being during symptomatic phases by helping reduce the overall symptom burden linked to allergen exposure.

Regulatory References

  1. NIH MedlinePlus overview of Rash Evaluation

Eligibility and Restrictions for Use

Eligibility for TRUE Test

TRUE Test is indicated for use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older whose clinical history suggests a sensitivity to one or more of the test's allergens.

Eligibility Status Description Restriction Context
Contraindicated Must not be used in patients with a history of severe allergic reaction (systemic and/or local) to any of the test components. Must not be applied to injured, inflamed, or severely dermatitic skin at the proposed test site. Known Hypersensitivity, Skin Integrity
Use Restricted The test should only be applied to healthy skin free of conditions that may interfere with results. Use requires careful consideration in patients with a known history of anaphylactoid reactions. Skin Condition, Allergy Risk
Not Recommended Pregnancy and Lactation: Use is not recommended due to a lack of data on safety for the mother and child. Immunosuppressant Medication: Testing should be postponed for patients receiving systemic immunosuppressants (like certain doses of oral corticosteroids), as these may suppress a true positive reaction. Physiological State, Concomitant Treatment
Age Restriction Only for use in patients 6 years of age and older. Safety and effectiveness have not been established in children younger than 6 years old. Pediatric Use

Testing must be avoided on skin that has been recently exposed to UV light or tanning beds for at least three weeks prior to application.

What should I know about interactions with other medicines?

The TRUE Test is a diagnostic patch system that elicits a local delayed hypersensitivity reaction, and its officially documented interactions are limited to substances that interfere with this required local immune response, potentially compromising test validity. Regulatory information specifies substances and procedural constraints to manage this interaction risk.

Official Interaction Domains

Category Regulatory Constraint Context
Systemic Immunosuppression Administration of the test is precluded while receiving systemic glucocorticoids or cyclosporines due to the risk of suppressing the skin reaction, leading to false-negative results.
Localized Pharmacodynamic Suppression Agents applied directly to the skin, such as high-potency topical corticosteroids, must be avoided at the application site for a specified period (typically one to two weeks) before testing.

Documented Interaction Statements

  • The use of systemic corticosteroids or other systemic immunosuppressant agents may result in a diminished diagnostic reaction, as stated in official labeling.
  • Timing rules require the cessation of topical corticosteroids at the application site to ensure the skin is capable of mounting a necessary diagnostic response.
  • The regulatory profile reports no documented pharmacokinetic interactions involving systemic clearance, CYP enzymes, or drug transporters, consistent with the product's non-systemic administration.
  • Exposure to ultraviolet (UV) light on the test area must be avoided for a period before application, as it is documented to interfere with local skin reactivity.

Mechanism of Action

The TRUE Test mechanism centers on the inhibition of the Protein X Receptor (PXR). Following systemic distribution, the active compound preferentially binds to the intracellular ligand-binding domain of PXR, functioning as a highly specific competitive antagonist. This binding event prevents the typical agonistic interaction between PXR and its endogenous ligands, leading to a conformational change that inactivates the receptor. The now-inactive PXR complex is unable to translocate to the nucleus and dimerize with the Retinoid X Receptor (RXR). Consequently, the drug prevents the PXR/RXR heterodimer from binding to Xenobiotic Response Elements (XREs) within the promoter regions of target genes. This blockade modulates the transcription of key enzymes in the CYP450 metabolic pathway and ABC drug transporters, resulting in an altered profile of hepatic phase I and phase II metabolic enzyme expression. The overall system-level consequence is a controlled, targeted perturbation of the PXR-mediated transcriptional cascade.

Dosage and Administration Information

The TRUE Test system is used according to a standardized, time-dependent protocol. As a diagnostic agent, it is administered solely via the epicutaneous route, meaning the test panels are applied directly to the skin. The official procedure mandates the single application of the entire three-panel system, which contains 35 standardized allergens and a negative control, per testing event. This ready-to-use form does not require any preparation or dilution.


Administration Timing and Schedule

The correct administration of the TRUE Test follows a strictly timed regimen.

Procedural Requirement Official Timing & Condition
Route of Application Topical (Epicutaneous)
Duration of Application Approximately 48 hours
Definitive Reading 72 to 96 hours after initial application
Approved Age Group 6 years of age and older

The test sites must be located on healthy skin of the back, specifically avoiding areas that are scarred, contain active lesions, or have had recent sun exposure, which ensures the integrity of the diagnostic results. The adhesive panels are removed after the 48-hour period, and a definitive evaluation of the reaction is required to take place later, between 72 and 96 hours after the initial application. This structured sequence defines the complete use protocol for identifying contact allergens.

Recent Clinical Evidence

Research evidence / Overview of studies for TRUE Test

Evidence for use in Diagnosing Allergic Contact Dermatitis (ACD)

Research examined the TRUE Test as a method for characterizing sensitization to specific substances relevant to Allergic Contact Dermatitis (ACD). The evidence base includes non-randomized prospective studies and multi-center comparative studies, which look at the system's standardized diagnostic approach in clinical settings. This research explored outcomes related to the local physical discomfort and inflammatory or irritative states measured at the application site.

Studies monitored patterns and reported measurements of the delayed immune response (the positive skin reaction) during the observed periods. Comparative research explored the system by measuring its diagnostic agreement (concordance) against other established patch testing methods.

The available research provides context about the diagnostic patterns observed in groups of people studied, but it does not determine individual predictions about a patient's personal outcome or prognosis.

Types of Clinical Studies and How Diagnostic Outcomes Were Measured

The clinical studies relevant to the TRUE Test were largely designed to be observational and comparative. Researchers used these designs to assess the system's ability to produce standardized information across different clinics and populations. Studies monitored diagnostic parameters such as concordance (agreement) and assessed diagnostic yield when compared to other testing methods.

Studies monitored outcomes based on readings of the skin's delayed response to the allergens, typically assessed by a healthcare professional. These studies focused on episodes where symptoms become more noticeable—specifically at the reaction site—to establish the system's baseline diagnostic criteria.

Evidence in Different Age Groups

Research was evaluated in various groups to understand the system's application across different patient types. The available data describe that studies included both adults (typically 18 years and older) and pediatric populations (specifically individuals aged 6 through 17 years of age).

While the system was evaluated in these different age groups, evidence is limited regarding the diagnostic patterns for highly specific patient groups, such as those with certain complex coexisting skin conditions. Study results reflect the specific conditions and group patterns under which they were conducted, and research does not determine personal diagnostic outcomes.

Observation Period and Follow-up Data

Research exploring short-term changes is relevant in evidence describing how diagnostic information is measured. Findings are primarily derived from studies observing responses over a defined time interval.

Follow-up durations were limited to the standard period needed for diagnosis, which includes readings at 48 hours (when the patch is removed) and a final assessment, typically at Day 7. There is limited information for long-term outcomes. Evidence highlights what is known during the diagnostic window, but information regarding subsequent avoidance strategies or sustained patient-reported outcomes beyond that period is not fully established.

Key Limitations and Areas for Further Research

The most significant research limitation is that the results apply only to the populations studied and only to the fixed set of 35 allergens plus the control on the panel. The evidence quality varies across studies, but all studies share the inherent limitation that they do not address allergic sensitization to any substances or allergens that are not included in the standardized test.

Data are still emerging for some areas. For instance, there is limited information for long-term outcomes following diagnosis. Researchers also note that the sample sizes for certain subgroups (like those with specific comorbidities) were modest, meaning subgroup findings are uncertain and more research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about TRUE Test (FAQ)

Q: Is the TRUE Test different from a standard skin prick test for allergies?

Official information indicates that the T.R.U.E. Test is used to help diagnose Allergic Contact Dermatitis (ACD), which is a delayed-type hypersensitivity reaction. This process is different from a standard skin prick test. Prick tests are typically used to check for immediate allergic reactions, while the T.R.U.E. Test assesses a delayed response that takes several days to appear.

Q: What is the role of the negative control patch on the TRUE Test?

According to the official product information, the T.R.U.E. Test includes one negative control patch that contains no allergens. The purpose of this control is to help confirm that any reaction at a test site is caused by one of the allergens and not just irritation from the tape or the application process itself.

Q: Why is the test typically applied to the patient's back?

Regulatory guidance instructs that the test panels be applied to the healthy skin of the back. The back is often used because it provides a large surface area for the panels and is less likely to be affected by movement and friction.

Q: Is TRUE Test considered the standardized method for patch testing?

Regulatory documents describe the T.R.U.E. Test as a standardized, ready-to-use epicutaneous patch test system that provides a uniform dose of allergens to the skin. This unique design contributes to its standardization in identifying contact allergies.

Q: What is the difference between an allergic reaction and an irritant reaction on the test site?

Official documents acknowledge that irritant reactions can occur during testing and may sometimes be difficult for a professional to distinguish from a true allergic reaction. Irritant contact dermatitis is listed as a potential adverse reaction. If interpretation is unclear, a retest may be considered by the healthcare professional.

Q: What activities must be avoided while wearing the TRUE Test patches?

The official protocol advises avoiding excessive sweating and excessive physical activity during the testing period. The protocol recommends limiting these activities to help maintain adhesion of the panels and prevent the loss of test material.

Q: Are there any specific lotions or creams that must be avoided on the back before the test?

The official label describes the requirement to avoid the use of alcohol or other irritating substances on the skin before testing. Clinical instructions also advise stopping general moisturizers, lotions, or creams in the area for a specified period prior to application.

Q: How is the skin prepared just before the TRUE Test panels are applied?

Regulatory guidance describes that the test should only be applied to healthy skin that is free of scars, acne, or dermatitis. The label describes the requirement to avoid applying the test to recently tanned or sun-exposed skin, and to avoid using alcohol or other irritating substances on the skin beforehand.

Q: How are the positive reactions on the test site graded or measured?

Official information indicates that the evaluation of positive reactions is based on the method recommended by the International Contact Dermatitis Research Group (ICDRG). This group uses a specific ranking scale to grade the intensity of the delayed immune response.

Q: What does a 'negative' result on the TRUE Test mean for a patient?

A negative result indicates that the patient did not react to the 35 specific allergens contained on the test panels. However, the official label notes that negative results do not rule out the possibility of sensitivity to other allergens not included on the test.

Q: Are there any known long-term side effects from the components of the TRUE Test?

The official label warns of Persistent Reactions which may remain visible for weeks or months after the patches are removed. Regulatory studies focused on the diagnostic period; therefore, official information does not contain sufficient data regarding outcomes beyond the standard follow-up period.

Q: What is the current state of research evidence for the accuracy of the TRUE Test in diverse populations?

Regulatory data confirm that the T.R.U.E. Test has been studied in both adults and pediatric populations (ages 6 through 17). Clinical studies were largely designed to assess diagnostic performance based on frequencies of positive, negative, irritant, and doubtful reactions.

Q: How long has the TRUE Test been an established diagnostic tool for contact dermatitis?

Studies and official information indicate that the T.R.U.E. Test is a result of many years of research aimed at creating a standardized patch testing system. The FDA has approved multiple versions of the test system, reflecting its established role as a standardized aid in diagnosis.

Q: Is it possible to shower or get the test area wet during the testing period?

The official protocol advises against getting the panels and surrounding area wet. Therefore, activities like showering, bathing, or swimming are not allowed during the 48-hour application period to maintain the adhesion of the panels.

Q: What steps should be taken if a TRUE Test patch begins to loosen or fall off?

The official instructions indicate that if necessary, a healthcare professional may use hypoallergenic surgical tape for increased adhesion around the outside edges. If the patch significantly loosens, the protocol is for the patient to notify their healthcare provider.

Q: What is the purpose of the medical pen markings placed around the patches?

Regulatory documents describe that medical marking pen markings are made on the skin to indicate the exact location of the patch sites. These markings are necessary to allow the physician to align and properly evaluate any reactions after the panels are removed.

Q: What happens if a patient sweats a lot while the TRUE Test patches are on?

The official label describes the requirement to avoid excessive sweating during the testing period to maintain sufficient adhesion. Excessive moisture could lift the patches and potentially interfere with the test results.

Q: Is it normal to feel a restrictive or strange feeling from the patches on the back?

The official label notes Tape Irritation as a common adverse reaction. Clinical instructions mention that test sites may be itchy and uncomfortable, which is related to the common adverse effect of skin irritation from the tape.

Q: Is it okay to use an electric shaver to remove hair from the test site beforehand?

If excessive body hair is present at the proposed test site, the official protocol states that it should be removed with an electric shaver. The protocol includes an instruction not to use a razor, as this could irritate the skin and interfere with the test.

Q: What can cause a false-positive result in patch testing like the TRUE Test?

The official label notes that an irritant reaction may occur, which can potentially be difficult to distinguish from a true positive allergic reaction. Irritant contact dermatitis is listed as a potential adverse reaction that can complicate the interpretation of the test results.

Q: Can the test results change over time with repeat testing?

The official label states that the effect of repetitive testing with the T.R.U.E. Test is unknown. It also warns that sensitization or increased reactivity to one or more allergens may occur.

Q: Do common over-the-counter allergy pills (antihistamines) affect the TRUE Test results?

Clinical expert consensus documents indicate that oral antihistamines, such as common over-the-counter allergy pills, generally do not affect the diagnostic patch testing process. These medications are generally described as being able to be continued during the test.

How should TRUE Test be stored and disposed of?

How to Store and Dispose of T.R.U.E. Test

The T.R.U.E. Test system must be stored under refrigerated conditions between 2°C and 8°C (36°F and 46°F) to ensure the stability of the diagnostic allergens. The product must not be frozen.

Storage Requirements

The panels must remain sealed in the original foil pouch until the time of use for protection from light and moisture. The kit should always be kept out of the sight and reach of children.

Disposal

Since the system is used in a clinical setting, all components, including used patches, are classified as medical waste. Disposal of any unused, expired, or used T.R.U.E. Test panels must be carried out according to the established local and national regulations for handling biohazardous materials.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of TRUE Test found in:

A-Z Index: